Express Scripts (ESRX)

ESRX (NASDAQ:Health Services)
$84.80
pos +0.00
+0.00%
Today's Range: 84.42 - 85.42 | ESRX Avg Daily Volume: 3,893,700
Last Update: 01/23/15 - 3:59 PM EST
Volume: 0
YTD Performance: 0.15%
Open: $0.00
Previous Close: $84.99
52 Week Range: $64.64 - $86.64
Oustanding Shares: 733,910,000
Market Cap: 62,375,010,900
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 12 12
Moderate Buy 3 3 3 2
Hold 5 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.63 1.55 1.55 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 34.00
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
34.00 34.10 26.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.07% 13.93% 64.15%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.90 1.31 0.32
Net Income 40.80 0.60 0.17
EPS 28.00 0.04 0.01
Earnings for ESRX:
EBITDA 6.00B
Revenue 104.10B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.38 $1.15 $4.88 $5.44
Number of Analysts 14 9 16 16
High Estimate $1.40 $1.21 $4.90 $5.55
Low Estimate $1.37 $1.11 $4.87 $5.35
Prior Year $1.12 $0.99 $4.33 $4.88
Growth Rate (Year over Year) 23.47% 16.50% 12.70% 11.55%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.
Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Here's the best way to play them.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
It might be good for consumers, but not for the stock.
Bearish
Sep 11, 2014 | 6:50 AM EDT
ESRX was downgraded from Buy to Neutral, Goldman Sachs said. $75 price target. Core business is facing fading growth drivers.

Stick With What Is Working Real Money Pro($)

Here are a few stocks I have made solid calls on recently that have moved up.
Bearish
Jul 30, 2014 | 8:16 AM EDT
ESRX price target lowered from $86 to $80, Jefferies said. Buy rating. Risk of incremental contract turnover.

Columnist Conversations

The result of the Greek election looks likely to add to volatility in the euro's exchange rate to the dollar. ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.